ÁÖ½Äȸ»ç ¸ÞŸ½áÄ¡

[¹ÙÀÌ¿ÀÁ¦¾à ´ë±â¾÷]Business Development Manager

¸ðÁýºÎ¹® ¹× ÀÚ°Ý¿ä°Ç

¸ðÁýºÎ¹® ´ã´ç¾÷¹« ÀÚ°Ý¿ä°Ç Àοø
Business Development Manager

[´ã´ç¾÷¹«]

¢Ã´ã´ç¾÷¹«
▪ Pipeline / Product / Platform TechnologyÀÇ µµÀÔ ÃßÁø Èĺ¸ ¹ß±¼, ºÐ¼®, Æò°¡
- CNS(ÁßÃ߽Űæ°è) ¹× Ç×¾ÏÁ¦(Oncology) ºÐ¾ßÀÇ µµÀÔ ÃßÁø Èĺ¸ Asset (pipeline ¹× product) and/or ±â¹Ý±â¼úÀÇ Å½»ö ¹× ¹ß±¼ (Screening/Scouting)
- À¯°ü ºÎ¼­µé °úÀÇ Çù¾÷À» ÅëÇÑ »ó¼¼ °ËÅä (Due Diligence)¹× Æò°¡ (Evaluation)¼öÇà
▪ Partnering (Licensing Out)
- º¸À¯ pipeline (Clinical or Pre-Clinical)ÀÇ ÆÄÆ®³Ê¸µ ÃßÁø Áغñ ÀÛ¾÷ – Non-confidential/Confidential Data Package ÀÛ¼º ¹× eDD room ±¸¼º/°ü¸® µî
- Potential Customer Ž»ö, ¼±º° ¹× Á¢ÃË, DD ´ëÀÀ, ÆÄÆ®³Ê¸µ term ÀÛ¼º ¹× °è¾à ü°á ÃßÁø
▪ Pharmaceutical Market ¹× Business ȯ°æÀÇ Intelligence ¹× Insight È®º¸
- ¹ÙÀÌ¿À¡¤Á¦¾à ¾÷°èÀÇ Business (Deal, ÆÄÆ®³Ê¸µ µî) events ¿¡ ´ëÇÑ ½ÉÃþ Á¶»ç/ºÐ¼® ¼öÇà
- ¹ÙÀÌ¿À¡¤Á¦¾à ¾÷°èÀÇ Áß¿ä °á°ú ¹ßÇ¥ eventµé(ÀÓ»ó°á°ú ¹× °¢Á¾ Impact ÀÖ´Â study °á°ú ¹ßÇ¥ µîµî) ¿¡ ´ëÇÑ ºÐ¼®/Æò°¡ º¸°í¼­ ÀÛ¼º – Insight Á¦°ø
- À¯¸Á compound µîÀÇ ÀÓ»ó/ÀüÀÓ»ó data¸¦ ºÐ¼®ÇÏ¿© »ç¾÷ Àü·«¿¡ Ȱ¿ë °¡´ÉÇÑ Insight Á¦°ø
- ÁÖ¿ä (Àü»ç Àü·«°ú Aligned µÈ) Indication/Therapeutic Area¿¡ ´ëÇÑ Landscape report ¹ß°£
▪ °æ¿µÁø º¸°í ÀÚ·á ÀÛ¼º
- µµÀÔ ÃßÁø Èĺ¸ÀÇ ¹ß±¼/ÃßÁø °¡´É¼º Æò°¡, ºÐ¼® º¸°í¼­ ÀÛ¼º
- (ÇÊ¿ä½Ã) ÆÄÆ®³Ê¸µ activity ¿¡ ´ëÇÑ °èȹ, °á°ú, ÇöȲ µî¿¡ ´ëÇÑ º¸°í¼­ ÀÛ¼º

¢ÃÀÚ°Ý¿ä°Ç
[Çʼö ¿ä°Ç]
▪ Àü°ø : »ý¸í°úÇÐ, ¾àÇÐ, »ý¹°ÇÐ µî Á¦¾à/¹ÙÀÌ¿À °ü·Ã Àü°ø
▪ Çз : ¼®»ç ÀÌ»ó, MBA Áö¿ø °¡´É(MBA ÇÐÀ§ ¼ÒÁöÀÚ´Â »ý¸í°úÇÐ °ü·Ã Çлç Àü°ø ù±), ¹Ú»ç Áö¿ø °¡´É
▪ °æ·Â : À¯°ü °æ·Â ¸¸ 6³â~9³â(¼±ÀÓ3³âÂ÷~Ã¥ÀÓ2³âÂ÷)
▪ ¿µ¾î ±¸»ç ´É·Â(¸»ÇÏ±â ¹× ¾²±â Æ÷ÇÔ) ¿ì¼öÀÚ·Î, ±Û·Î¹ú ȯ°æ¿¡¼­ È¿°úÀûÀÎ Ä¿¹Â´ÏÄÉÀÌ¼Ç °¡´ÉÇÑ ÀÚ
▪ ÇØ¿Ü ÃâÀå °á°Ý »çÀ¯ ¾ø´Â ÀÚ

[¿ì´ë ¿ä°Ç]
▪ CNS / Oncology ¿¬±¸ °æ·Â ¹× ÀÓ»ó ¼öÇà °æ·Â º¸À¯
▪ Á¦¾à ¶Ç´Â ÇコÄɾî ȸ»ç Business Development or Licensing In/Out ºÎ¼­ ±Ù¹« °æ·Â º¸À¯
▪ Á¦¾à ¶Ç´Â ÇコÄÉ¾î »ê¾÷¿¡¼­ÀÇ ½ÃÀå ¹× °æÀï»ç/Compound/Pipeline/Product ºÐ¼® °æÇè º¸À¯
▪ ´Ù¾çÇÑ ¾÷¹«¸¦ ¿ì¼±¼øÀ§¿¡ µû¶ó ó¸®Çϸç Á¤ÇØÁø ±âÇÑ ³»¿¡ °á°ú¸¦ µµÃâÇÑ °æÇè º¸À¯
▪ µ¥ÀÌÅÍ ºÐ¼® (¿¹: GlobalData, EvaluatePharma µî Database) ¹× ÇÁ·¹Á¨Å×ÀÌ¼Ç µµ±¸ (¿¹: Excel, PowerPoint µî) »ç¿ë ´É¼÷
▪ ±Û·Î¹ú ÄÁÆÛ·±½º/³×Æ®¿öÅ·/ÆÄÆ®³Ê¸µ °æÇè (¿¹: BIO, JP Morgan Health Conference µî) º¸À¯ÀÚ

[ÀÚ°Ý¿ä°Ç]

°æ·Â: °æ·Â 6~9³â
ÇзÂ: ¼®»çÁ¹¾÷
Á÷¹«±â¼ú: Business Development Manager, Licensing Out


0 ¸í

±Ù¹«Á¶°Ç

  • °í¿ëÇüÅÂ: Á¤±ÔÁ÷
  • ±Þ¿©Á¶°Ç: ȸ»ç³»±Ô

ÀüÇü´Ü°è ¹× Á¦Ãâ¼­·ù

  • ÀüÇü´Ü°è: ¼­·ùÀüÇü > ¸éÁ¢ÁøÇà > ÃÖÁ¾½É»ç > ÃÖÁ¾ÇÕ°Ý
  • Ãß°¡ Á¦Ãâ¼­·ù
    À̷¼­, ÀÚ±â¼Ò°³¼­, °æ·Â±â¼ú¼­

Á¢¼ö¹æ¹ý

  • Á¢¼ö¹æ¹ý: ÀÎÅ©·çÆ® Á¢¼ö, À̸ÞÀÏ
  • Á¢¼ö¾ç½Ä: ÀÎÅ©·çÆ® À̷¼­

±âŸ À¯ÀÇ»çÇ×

  • ÀÔ»çÁö¿ø¼­ ¹× Á¦Ãâ¼­·ù¿¡ ÇãÀ§»ç½ÇÀÌ ÀÖÀ» °æ¿ì ä¿ëÀÌ Ãë¼ÒµÉ ¼ö ÀÖ½À´Ï´Ù.

00